					(20000000000000000000000000000000000000	
61	ostitute for form 1449/PTO			Complete if Known		
Sui	ostitute for form 1449/PTO			Application Number	10/530,753	
l ii	NFORMATION	1 DI	SCLOSURE	Filing Date	October 2, 2003	
	STATEMENT I			First Named Inventor	Mariagrazia PIZZA	
	,			Art Unit	1645	
(Use as many sheets as necessary)				Examiner Name	B. Gangle	
Sheet	Sheet 3 of 5		5	Attorney Docket Number	223002100300	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS									
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,					
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	1 (0) 10	Where Relevant Passages Or Relevant Figures Appear	T ⁶				

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The region of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	48.	ABAD et al. (2008). "PorB2/3 Protein Hybrid in Neisseria meningitidis," Emerging Infectious Diseases, 14(4):688-689.	
	49.	ALA'ALDEEN et al. (1996). "The Meningococcal Transferrin-binding Proteins 1 and 2 are Both Surface Exposed and Generate Bactericidal Antibodies Capable of Killing Homologous and Heterologous Strains," Vaccine 14(1):49-53.	
	50.	BARTSEVICH et al. (March 7, 1997). "Molecular Identification of a Novel Protein That Regulates Biogenesis of Photosystem I, a Membrane Protein Complex," The Journal of Biological Chemistry 272(10):6382-6387.	
	51.	BETHELL et al. (2002). "Meningococcal vaccines," Expert Review of Vaccines 1(1):75-84.	
	52.	BOSLEGO et al. (1991). "Gonorrhea Vaccines" Chapter 17 in Vaccines and Immunotherapy, S. Cryz (Ed.). pp. 211-223.	
	53.	BYGRAVES et al. (1992). "Analysis of the Clonal Relationships Between Strains of Neisseria Meningitidis by Pulsed Field Gel Electrophoresis," Journal of General Microbiology 138:523-531.	
	54.	CANN et al. (1989). "Detection of Antibodies to Common Antigens of Pathogenic and Commensal Neisseria Species," Journal of Medical Microbiology 30:23-30.	
	55.	CAUGANT et al. (1987). "Genetic Structure of Neisseria Meningitidis Populations in Relation to Serogroup, Serotype, and Outer Membrane Protein Pattern," Journal of Bacteriology 169(6):2781-2792.	
	56.	CHRISTODOULIDES et al. (1994). "Immunization with a Multiple Antigen Peptide Containing Defined B- and T-Cell Epitopes: Production of Bacterial Antibodies Group B Neisseria Meningitidis," Microbiology 140:2951-2960.	
	57.	COONEY et al. (1993). "Three Contiguous Lipoprotein Genes in Pasteurella haemolytica A1 which are Homologous to a Lipoprotein Gene in Haemophilus Influenza Type B," Infection and Immunity 61(11):4682-4688.	

61	ostitute for form 1449/PTO			Complete if Known		
Sui	ostitute for form 1449/PTO			Application Number	10/530,753	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	October 2, 2003	
	TATEMENT E			First Named Inventor	Mariagrazia PIZZA	
		. ,	AI I LIOAIII	Art Unit	1645	
	(Use as many sh	eets as	s necessary)	Examiner Name B. Gangle		
Sheet	et 4 of 5		Attorney Docket Number	223002100300		

58.	DEMPSEY et al. (1991). "Physical Map of the Chromosome of Neisseria gonorrhoeae FA1090 with Locations of Genetic Markers, including Opa and Pil Genes," Journal of Bacteriology 173(17):5476-5486.	
59.	DEVRIES et al. (August 1996). "Invasion of Primary Nasopharyngeal Epithelial Cells by Neisseria meningitidis is Controlled by Phase Variation of Multiple Surface Antigens," Infection and Immunity 64(8):2998-3006.	
60.	ELLIS (1988). "New Technologies for Making Vaccines" in Vaccines. Plotkin et al. (Eds.) pp.568-575.	
61.	FENG et al. (1996). "P55, an Immunogenic but Nonprotective 55-Kilodalton Borrelia burgdorferi Protein in Murine Lyme Disease," Infection and Immunity. 64(1):363-365.	
62.	GERVAIS et al. (1992). "Putative Lipoprotein Yaec Precursor," Database Swissport Acc No: p28635.	
63.	GUILLEN et al. (1996). "Expression in Escherichia Coli and Immunological Characterization of a Hybrid Class I-P64K Protein from Neisseria Meningitidis," Biotecnologia Aplicada13(4):271-275.	
64.	HERBERT et al. (1995). The Dictionary of Immunology. Academic Press: London 4 th edition, 3 pages.	
65.	HERBERT et al. (1985). The Dictionary of Immunology. Academic Press: London 3 rd edition, pp. 58-59.	
66.	HOLMES, E. (2001). "PSMA Specific Antibodies and their Diagnostic and Therapeutic Use," Expert Opinion on Investigational Drugs 10(3): 511-519.	
67.	JACOBSSON et al. (2009). Vaccine. 27:1579-1584.	
68.	JOLLEY et al. (2007). "Molecular typing of meningococci: recommendations for target choice and nomenclature," FEMS Microbiol. Rev. 31:89-96.	
69.	LEGRAIN et al. (1995). "Production of Lipidated Meningococcal Transferrin Binding Protein 2 in Escherichia Coli," Protein Expression and Purification 6:570-578.	
70.	MAIDEN et al. (1998). "Multilocus Sequence Typing: a Portable Approach to the Identification of Clones within Populations of Pathogenic Microorganisms," Proceedings of the National Academy of Sciences USA 95:3140-3145.	
71.	MORLEY et al. (2002). "Vaccine prevention of meningococcal disease, coming soon?" Vaccine 20:666-687.	
72.	NI et al. (1992). "Phylogenetic and Epidemiological Analysis of Neisseria meningitidis Using DNA Probes," Epidemiology and Infection 109:227-239.	
73.	PERKINS et al. (1998). "Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland," The Journal of Infectious Disease 177:683-691	
74.	PERRETT et al. (2005). "Towards an improved serogroup B Neisseria meningitidis vaccine," Expert Opinion on Biological Therapy 5(12):1611-1625.	
75.	PETTERSSON et al. (1999). "Sequence Variability of the Meningococcal Lactoferrin-binding Protein LbpB," Gene 231:105-110.	
76.	PIZZA et al. (March 10, 2000). "Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing," Science 287(5459):1816-1820.	
77.	POOLMAN et al. (1985). "Colony Variants of Neisseria Meningitidis Strain 2996 (B:2b:P1.2): Influence of Class-5 Out Membrane Proteins And Lipolysaccharides," J. Med. Microbiol 19:203-209.	
78.	POOLMAN et al. (1988). "Outer membrane protein serosubtyping of Neisseria meningitidis," European Journal of Clinical Microbiology and Infectious Diseases 7(2):291-292.	
79.	POOLMAN (1995). "Development of a Meningococcal Vaccine," Infectious Agents and Disease 4:13-28.	
80.	RENAULD-MONGENIE et al. (1997). "Identification of Human Transferrin-Binding Sites Within	

Sul	ostitute for form 1449/PTO			Complete if Known		
Sui	DStitute for form 1449/FTO			Application Number	10/530,753	
11	NFORMATION	l Di	SCLOSURE	Filing Date	October 2, 2003	
	STATEMENT E			First Named Inventor	Mariagrazia PIZZA	
		·	AI I LIOAIII	Art Unit	1645	
(Use as many sheets as necessary)				Examiner Name	B. Gangle	
Sheet	5	of	5	Attorney Docket Number 223002100300		

	Meningococcal Transferrin-Binding Protein B," J. Bacteriology 197(20):6400-6407.	
81.	ROITT, I. et al. (1993). Immunology. Mosby: St. Louis, 4 th edition, pages 7,7-7,8.	
82.	ROSENQVIST et al. (1995). "Human Antibody Response to Meningococcal Outer Membrane Antigens after Three Doses of the Norwegian Group B Meningococcal Vaccine," Infection and Immunity 63(12):4642-4652.	
83.	SEILER et al. (1996). "Allelic polymorphism and site-specific recombination in the opc locus of Neisseria meningitidis," Molecular Microbiology 19(4):841-856.	
84.	TELFORD (June 2008). "Bacterial Genome Variability and Its Impact on Vaccine Design," Cell Host & Microbe 3(6):408-416.	
85.	TETTELIN et al. (2006). "Towards a universal group B Streptococcus vaccine using multistrain genome analysis," Expert Rev Vaccines 25:687-694.	
86.	TETTELIN et al. (March 10, 2000). "Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58," Science 287(5459):1809-1815.	
87.	THOMPSON et al. (1994). "Clustal W: Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-specific Gap Penalties and Weight Matrix Choice," Nucleic Acids Research 22(22):4673-4680.	
88.	THOMPSON et al. (1998). "Multiple Sequence Alignment with Clustal X," Trends in Biochemical Sciences 23:403-405.	
89.	VAN DER LAY et al. (1992). "Construction of a Multivalent Meningococcal Vaccine Strain Based on the Class I Outer Membrane Protein," Infection and Immunity 60(8): 3516-3161.	
90.	VAN DER LAY et al. (1995). "Construction of Neisseria Meningitidis Strains Carrying Multiple Chromosomal Copies of the PorA Gene for Use in Production of a Multivalent Outer Membrane Vesicle Vaccine," Vaccine 13(4): 401-107.	
91.	VIRJI et al. (1992). "Variations in the Expression of Pili: the Effect on Adherence of Neisseria meningitidis to Human Epithelial and Endothelial Cells," Molecular Microbiology 6:1271-1279.	
92.	WOLFF et al. (1992). "Phylogeny and Nucleotide Sequence of a 23S rRNA Gene from Neisseria gonorrhea and Neisseria meningitidis," Nucleic Acids Research 20(17):4657.	

TE. Hrigh (Egnalo)	Date Considered	03/17/2010
--------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.